<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2152">
  <stage>Registered</stage>
  <submitdate>22/10/2008</submitdate>
  <approvaldate>22/10/2008</approvaldate>
  <nctid>NCT00778609</nctid>
  <trial_identification>
    <studytitle>Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache</studytitle>
    <scientifictitle>A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, 2-arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Microgynon on Hormone Withdrawal-associated Symptoms After 6 Cycles of Treatment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>310787</secondaryid>
    <secondaryid>91550</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Oral Contraceptive</healthcondition>
    <healthcondition>Headache</healthcondition>
    <healthcondition>Pelvic Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - EV/DNG (Qlaira, BAY86-5027)
Treatment: drugs - Encapsulated Microgynon + Placebo

Experimental: Arm 1 - 

Active Comparator: Arm 2 - 


Treatment: drugs: EV/DNG (Qlaira, BAY86-5027)
Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval

Treatment: drugs: Encapsulated Microgynon + Placebo
Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare SH T00658ID (Qlaira) to Microgynon with regard to changes in frequency and intensity of the hormone withdrawal associated symptoms headache and pelvic pain on cycle days 22-28 combined into a single endpoint</outcome>
      <timepoint>Baseline to cycle 6</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rescue medication consumption</outcome>
      <timepoint>Baseline to cycle 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency and intensity of other hormone-related symptoms (bloating or swelling, breast tenderness, and nausea or vomiting) during cycle days 22 to 28</outcome>
      <timepoint>Baseline to cycle 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Prevalence of individual hormone-related symptoms during cycle days 1 to 21</outcome>
      <timepoint>Baseline to cycle 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Prevalence of individual hormone-related symptoms during hormone-free interval, i.e. cycle days 27+28 for EV/DNG capsules and cycle days 22 to 28 for the comparator</outcome>
      <timepoint>Baseline, cycle 3 and cycle 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in the average of the 3 highest VAS values of the hormone withdrawal associated symptoms pelvic pain or headache during cycle days 22 to 28 from baseline to cycle 3</outcome>
      <timepoint>Baseline to cycle 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bleeding pattern and cycle control</outcome>
      <timepoint>Throughout</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>QoL Questionnaires: Psychological General Well-Being Index (PGWBI), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and Clinical Global Index (CGI)</outcome>
      <timepoint>Baseline, cycle 2 and cycle 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AEs and SAEs. Concomitant medication. Vital signs (heart rate and blood pressure). Body weight</outcome>
      <timepoint>Throughout</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>General physical and gynecological examination</outcome>
      <timepoint>Screening and Final Visit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age between 18 and 50 years (inclusive) at visit 1, for smokers up to 35 years
             (inclusive)

          -  Otherwise healthy female subjects requesting contraception and currently using a
             levonorgestrel, gestodene or desogestrel containing oral contraceptive in a 21-day
             regimen and suffering from at least moderate pelvic pain, headache or both defined by
             an average value of &gt;/= 35 mm for the 3 highest values on a visual analogue scale
             during cycle days 22-28.

          -  Normal or clinically insignificant cervical smear not requiring further follow up (or
             a normal result obtained within the last 6 months before screening)

          -  Able to tolerate ibuprofen and willing to use only ibuprofen supplied for the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Women with any contraindication for oral contraceptive use</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>449</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital> - Ashfield</hospital>
    <hospital> - Blacktown</hospital>
    <hospital> - Caringbah</hospital>
    <hospital> - Sydney</hospital>
    <hospital> - Fortitude Valley</hospital>
    <hospital> - Kipparing</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Norwood</hospital>
    <hospital> - Clayton</hospital>
    <hospital> - Nedlands</hospital>
    <hospital> - Subiaco</hospital>
    <postcode>2031 - Ashfield</postcode>
    <postcode>2148 - Blacktown</postcode>
    <postcode>2229 - Caringbah</postcode>
    <postcode>2031 - Sydney</postcode>
    <postcode>4006 - Fortitude Valley</postcode>
    <postcode>4021 - Kipparing</postcode>
    <postcode>5005 - Adelaide</postcode>
    <postcode>5065 - Norwood</postcode>
    <postcode>3163 - Clayton</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brignoles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Maison Lafitte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Olivet</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Germain En Laye</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Seclin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tarare</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Württemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Niedersachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen-Anhalt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schleswig-Holstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>México</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Sonora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico, D.F.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>México, D.F.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Asturias</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel-Stadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cheshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>North Somerset</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottinghamshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Stratchclyde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the present study is to investigate whether women taking a new combined oral
      contraceptive pill (SH T00658ID, estradiol valerate/dienogest) experience fewer hormone
      withdrawal-associated symptoms such as pelvic pain or headache during their monthly cycle
      compared to a commonly used contraceptive pill (Microgynon).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00778609</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>